The story of Viagra presents a challenging picture for shareholders. While the initial launch generated massive profits, the end of its patent opened the floodgates to off-brand alternatives, dramatically eroding https://livebackpage.com/story7154669/sildenafil-and-big-pharma-a-volatile-opportunity